A comprehensive meta-analysis published in The Lancet Neurology has identified several gut microbial signatures that correlate with reduced risk of Alzheimer's disease progression. The study — spanning 14 cohorts across six countries and over 4,000 participants — found that individuals with higher relative abundance of Akkermansia muciniphila and Faecalibacterium prausnitzii showed measurably slower cognitive decline over a five-year follow-up period.
The mechanisms proposed centre on the gut-brain axis: both species are known producers of short-chain fatty acids (SCFAs) that cross the blood-brain barrier and modulate neuroinflammatory pathways. The authors suggest that SCFA production may attenuate the chronic low-grade neuroinflammation now widely implicated in Alzheimer's pathology.
For clinicians working in integrative and functional medicine, the findings reinforce the case for microbiome-targeted interventions — dietary modification, prebiotic supplementation, and targeted probiotic protocols — as adjuncts in the management of patients at elevated dementia risk. HOW Academy's upcoming Functional Medicine Foundations online course covers the gut-brain axis in depth, including the latest evidence on SCFA-mediated neuroprotection.